SEC Form 4	
------------	--

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

\_\_\_\_

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> Schwab Gisela				er Name <b>and</b> Ticke <u>ELIXIS, INC.</u>		Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner					
(Last) C/O EXELIXI	(First)	(Middle)		e of Earliest Transa I/2020	ction (Month/	Day/Year)	x	Director Officer (give title below) Pres, Prod Dev 8	Other below	(specify )		
				mendment, Date of	Original Filed	(Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)								Form filed by One	Penorting Pers	nn		
ALAMEDA	CA	94502										
,								Form filed by Mor Person	e than One Repo	orting		
(City)	(State)	(Zip)										
		Table I - No	n-Derivative	Securities Acc	quired, Dis	sposed of, or Benefic	ially (	Dwned				
Date			2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 a		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		

	Date (Month/Day/Year)			Code (Instr.		Disposed Of (D) (Instr. 3, 4 and 5)			Form: Direct (D) or Indirect (I) (Instr. 4)	Indirect Beneficial Ownership (Instr. 4)	
			Code	v	Amount	(A) or (D)	A) or D) Price Reported Transacti (Instr. 3 a			(1130.4)	
Common Stock	06/04/2020		М		100,000	A	\$1.7	425,963 <sup>(1)</sup>	D		
Common Stock	06/04/2020		<b>S</b> <sup>(2)</sup>		100,000	D	\$22.96 <sup>(3)</sup>	325,963	D		
Common Stock								14,880 <sup>(4)</sup>	I	By 401(k)	
Table II. Derivative Convision Annuired Dispensed of an Depeticially Owned											

## Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				-				-							
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Option (right to buy)	\$1.7	06/04/2020		М			100,000	07/20/2015 <sup>(5)</sup>	09/18/2021	Common Stock	100,000	\$0	200,000	D	

## Explanation of Responses:

1. Includes 55,494 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units and 841 shares of common stock acquired on April 30, 2020, pursuant to the Exelixis, Inc. 2000 Employee Stock Purchase Plan.

2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2019.

3. Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from \$22.47 to \$23.46. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 3 to this Form 4.

4. Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of June 3, 2020.

5. The option, representing the right to purchase a total of 500,000 shares of Exelixis, Inc. common stock, became fully exercisable on April 28, 2016.

Remarks:

## /s/ Jennifer Drimmer Rokovich,

Attorney in Fact

<u>06/05/2020</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.